Single Photon Emission Computed Tomography (SPECT) is a 3D nuclear medicine imaging technique that provides qualitative and quantitative physiologic measurements. As a complement to current practices, SPECT/CT is beneficial for earlier stage testing of pharmacokinetics, pharmacodynamics, disease/tissue targeting as well as later stage regulatory, biodistribution and drug metabolism studies.
Key advantages over pre-existing methods include:
• Non-invasive imaging of fine kinetics can be examined allowing establishment of a kinetic curve by tissue or even by tissue compartment (heterogeneity)
• 3-dimensionality with tissue localization
• Clinical translatability
• Simultaneous response to questions in different regions of a biologic and, therefore, address different questions simultaneously and more cost-effectively
• Tracer multiplexing - multiple isotopes of different energies can be used to address multiple simultaneous questions
The addition of SPECT leverages broad and deep expertise in design, execution and reporting of radiotracer nuclear medicine studies dating back to 2003 when we established the first microPET CRO capabilities.
SPECT radiotracers are effective clinical and non-clinical tools. We have access to a wide variety of clinical tracers (i.e. MDP, sestamibi) as well as many non-commercial options through our professional alliances. Benefits of these flexible tracers include:
- Single Photon Emission Computed Tomography (SPECT)
- Magnetic Resonance Imaging (MRI)
- Micro-Positron Emission Tomography (microPET)
- 2D Bioluminescence and Fluorescence
- Micro-Computed Tomography (microCT)
- Fluorescence Molecular Tomography (FMT)
- Mouse Dual Energy X-Ray Absorptiometry (DEXA)
- 2D X-Ray Radiography
